Loading
companiesCompany
Rhizen Pharmaceuticals
Rhizen Pharmaceuticals is a Swiss biotech, part of India's Incozen group, whose dual PI3K delta and gamma inhibitor tenalisib is being tested in T-cell lymphoma and breast cancer.
Also called: Rhizen Pharmaceuticals AGRhizen Pharmaceuticals SA
Overview
Rhizen Pharmaceuticals, based in Basel, discovers small molecules for cancer and immune disease. Tenalisib (RP6530) inhibits the delta and gamma isoforms of PI3K, which are enriched in lymphocytes and myeloid cells; it has been studied in relapsed T-cell lymphomas, in combination with romidepsin, and in hormone receptor-positive breast cancer. Rhizen also discovered the PI3K delta inhibitor umbralisib, later developed by TG Therapeutics.
Headquarters
Basel, CH
Scorecard
All companies#428of 1244 companies, score 8
- phase 1/2 +1
- modalities +2
- registry trials +5
0 approved, 0 in phase 3, 1 earlier, 0 targets, 7 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Oral PI3K inhibitor
Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer.
drugs
Phase 2Oral PI3K inhibitor